4 Ways To Avoid COA Source Revisions And Mitigate Risk In Your Global Clinical Trials

By Rebecca Weatherholtz, Director, TransPerfect Life Sciences Solutions

When an English source requires a revision after translations have begun, this can be a major challenge in maintaining set budgets and timelines in global COA clinical trials. Often, these revisions seem minor but can end up having a significant impact on the multiple languages in scope for a study. An often-overlooked aspect of source revisions is that in addition to increasing timelines and costs, they also add inherent risk to the quality of the translations. While source revisions cannot be completely avoided, there are ways to prevent many of them that will greatly increase the probability of a successful launch.